IMPOWER010

NCT02486718 📎

Regimen

Experimental
atezolizumab adjuvant
Control
best supportive care

Population

Resected stage IB-IIIA NSCLC post adjuvant chemo

Key finding

In PD-L1≥1% stage II-IIIA DFS HR 0.66 (0.50-0.88); first adjuvant IO signal

Source: PMID 34555333

Timeline

  • Enrollment start: 2015-10-31 📎

Guideline citations

  • NCCN NSCLC Version 5.2026 (p.94)
  • CSCO NSCLC 2025 ⚠️ OCR source